333 results about "Immune deficiency syndrome" patented technology

The invention relates to a method for successfully inducing cell chemokine receptor CCR5 genes to be mutated into CCR5-delta32 deletion-type genes with a new genome editing technology CRISPR-Cas9. CCR5 is an important receptor for human immunodeficiency viruses (HIV) to invade personal host cells. CCR5-delta32 deletion means deletion of 32 basic groups occurs in a CCR5 coding region, so that the sequence after the 185th amino acid is changed, and early termination occurs. CCR5-delta32 biallelic-gene homozygous deletion has natural resistance to HIV infection, and can not be infected by HIV. By means of the method, a slow virus packaging system and the CRISPR technology are used at the same time; as the slow virus infecting host range is wide, the method can be applied to cells such as bone marrow stem cells and CD4T cells, and the CCR5-delta32 deletion-type genes hopefully become medicine for treating acquired immune deficiency syndrome or other diseases.

The present invention provides a 4′-C-substituted-2-haloadenosine derivative represented by the following formula [I], [II], or [III]:(wherein X represents a halogen atom, R1 represents an ethynyl group or a cyano group, and R2 represents hydrogen, a phosphate residue, or a phosphate derivative residue). The present invention also provides a pharmaceutical composition containing the derivative and a pharmaceutically acceptable carrier therefor. Such derivative is useful as medicine for the treatment of Acquired Immune Deficiency Syndrome (AIDS).

The invention discloses a novel traditional Chinese medicine composition for treating the fatigue syndrome of sub-healthy people and the fatigue, the hypodynamia and the inferior immunologic function of a patient with acquired immune deficiency syndrome and a preparation method thereof. The main components of the traditional Chinese medicine composition comprise the following several raw materials of medicines: crude astragalus root, yam, white peony root, radix codonopsis pilosulae, angelica, solomonseal, ginseng, tuber fleeceflower, American ginseng, antler, aweto, ophiopogon root, Chinese wolfberry and prepared rehmannia root. The medicine composition can be prepared into any common oral preparation according to a conventional traditional Chinese medicine preparation method. The invention can obviously improve sub-health, fatigue syndrome, fatigue and hypodynamia of patients with acquired immune deficiency syndrome, enhances the self immunity and has the advantages of definite curative effect, obvious effect, convenient taking, quick acting, wide suitable crowd, no toxic or side effect and the like.

The invention relates to the field of gene therapy, in particular relates to sgRNA (singleguide Ribonucleic Acid), as well as a lentiviral vector constructed by the same and application thereof and specifically relates to sgRNA with SIVmac1A11 lentivirus as a framework to express SpCas9 protein and gene specificity. The sgRNA is applied to treating human and simian AIDS (Acquired Immune Deficiency Syndrome). A nucleotide sequence of the sgRNA is shown as SEQ ID NO.1 to 2. According to the sgRNA disclosed by the invention, a current most efficient CRISPR / Cas9 gene editing tool is utilized, a designed CXCR4 / CCR5 gene sgRNA locus has gene knockout activity superior to other loci reported by existing research, and the sgRNA is applied to gene therapy of SIV infected rhesus monkeys for the first time. Compared with ZFN and TALEN, the sgRNA has the advantages of being convenient to operate, low in cost and the like.

New methods are provided for suppressing the immune system and for treating immune related disorders. Therapies of the invention include administration of an FLT3 inhibitor compound to a subject in need thereof, such as a subject suffering from organ rejection, bone marrow transplant rejection, acquired immune deficiency syndrome, arthritis, aplastic anemia, graft-versus-host disease, Graves' disease, established experimental allergic encephalitomyelitis, multiple sclerosis, lupus, or a neurological disorder. Methods are also provided for screening therapeutic agents for treating immune disorders, including the use of a mouse having an elevated level of FLT3 receptor activity.

The invention discloses a CRISPR (clustered regularly interspaced short palindromic repeat) / Cas9 recombinant lentiviral vector containing gRNA sequence specifically targeting CCR5 and application thereof. A lentivirus of the CRISPR / Cas9 recombinant lentiviral vector containing gRNA sequence specifically targeting CCR5 gene Delta 32 region is constructed that the lentivirus can introduce cells into a CRISPR / Cas9 system specific to CCR5, double-chain breakage occurs to a specific site of CCR5 gene, a random mutation is introduced to a breakage site after repairing by means of nonhomogeneous recombinant terminal binding, and the mutation rate reaches 90% and above. As gRNA is a nonhomogeneous region of CCR5 and CCR2, detection shows that the missing efficiency of the two gRNAs is lower than 0.2%. Cells modified via the recombinant lentivirus have significantly decreased efficiency of HIV (human immunodeficiency virus) infection. The system is quick to construct, simple and low in price, and is applicable to gene therapy of acquired immune deficiency syndrome.

The invention discloses sgRNA for specific targeting of a human CXCR4 gene, a sgRNA-containing staphylococcus aureus CRISPR / SaCas9 system and a method for specific human CXCR4 gene knockout by the method. A target sequence of sgRNA is shown as any one of SEQ ID NO:1-4. sgRNA for specific targeting of the human CXCR4 gene and AAV-CRISPR / SaCas9 plasmids are connected to form a carrier and packaged into AAV infection cells, simplicity, convenience, high efficiency and specificity in CXCR4 gene knockout are realized, and accordingly the problem of limitation in adoption of SpCas9 targeted CXCR4 for treatment of acquired immune deficiency syndrome is effectively solved.

The invention provides a completely oral medicament for treating acquired immune deficiency syndrome (AIDS), comprising the following components: hedyotis diffusa, honeysuckle, meadowrueleaf corydalis root, dandelion, weeping forsythia, asparagus, ophiopogon root, figwort root, fresh rehmannia root, peach kernel, chuanxiong rhizome, zedoary, achyranthes root, dahurian patrinia herb, giant knotweed, stiff silkworm, isatis root, white peony root, polygonatum, bitter caramon, mistletoe, tortoise plastron, glossy privet fruit, oyster, pollen, salvia miltiorrhiza, tree peony bark, bupleurum, bitter orange, cimicifuga foetida, dried orange peel, amomum fruit, officinal magnolia bark, rose, songaria cynomorium herb, self-heal, medicine terminalia fruit, gromwell, licorice, chrysanthemum, castor bean, bullfrog gallbladder, baikal skullcap root, medicated leaven, malt, rice sprout, chicken's gizzard-skin, radish seed, scorch-fried crataegus, Chinese yam, astragalus root, bighead atractylodes rhizome, sealwort, dangshen, prepared rehmannia root, cornus fruit, tuckahoe, jujube, Chinese wolfberry, cistanche, dragon bone, oyster, epimedium, curculigo root, deerhorn glue, ginseng, donkey-hide glue, white fungus, angelica, spatholobus stem and turtle shell. The medicament provided by the invention not only can cure AIDS and has good therapeutic effect on AIDS, but also can prevent infection of AIDS.

The present invention relates to a pyrrolopyridine derivative represented by the Chemical Formula I, and a racemate or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and relates to an antiviral composition including the same as an active ingredient. The compound of the Chemical Formula I has excellent antiviral activity and selectivity for wild type and resistant HIV-1, and thereby is useful as a therapeutic agent for acquired immune deficiency syndrome (AIDS).

The invention relates to a polyamine micromolecular compound, comprising the following structures described in the specification, wherein M<x+> is 0, Zn<2+>, Ga<3+>, Gd<3+>, Ca<2+> or other divalent metal ions and trivalent metal ions; S is a reporter group (including a nuclide labeling prothetic group, a paramagnet, a fluorescein or a microvesicle), such as the nuclide labeling prothetic group: -<11>CH3, -CH2CH2<18>F, -CH2CH2(OCH2CH2)2NHCOC6H4<18>F-p or -CH2CH2(OCH2CH2)2NH-CH2CH2<18>F; R is -H, -OCH3, -OCH2CH3 or -Cl; and R1, R2, R3 and R4 are hydrogen, carboxyl, alkane, alkylene or heteroalkyl. The invention further relates to application of the compound in preparing cell death or apoptosis developers of target phosphatidyl serine (PS) and / or apoptotic cell early free Zn<2+>. The compound provided by the invention is a specific multiamine micromolecular developer for target phosphatidyl serine (PS) and / or apoptotic cell early free Zn<2+>, which can be used for monitoring curative effects of PS-related anti-tumor chemotherapy, radiotherapy, biological therapy and the like; the compound can be used for early differential diagnosis of neurodegenerative diseases (senile dementia and Parkinson's disease), cerebral apoplexy, AIDS (Acquired immune deficiency syndrome), thrombus, atheromatous plaque and myocardial infarction; and the compound can also be used for differential diagnosis and curative effect monitoring of other diseases related to PS expression in the cell death or apoptosis process, such as inflammation development and anti-inflammation therapeutic development.

Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and / or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to prepare antibodies, where both the polypeptides and antibodies may be employed as diagnostic reagents or in therapy, e.g., vaccines and passive immunization. The sequences provide detection of the viral infectious agents associated with the indicated syndromes and can be used for expression of antigenic polypeptides.

Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and / or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to prepare antibodies, where both the polypeptides and antibodies may be employed as diagnostic reagents or in therapy, e.g., vaccines and passive immunization. The sequences provide detection of the viral infectious agents associated with the indicated syndromes and can be used for expression of antigenic polypeptides.

The application describes an assay for the identification of small molecule modulators of integrin CD11b / CD18 and small molecules capable of modulating activity of this receptor. Such compounds may be used in certain embodiments for treating a disease or condition selected from inflammation, immune-related disorders, cancer, ischemia-reperfusion injury, stroke, neointimal thickening associated with vascular injury, bullous pemphigoid, neonatal obstructive nephropathy, and cardiovascular disease, or in other embodiments for the treatment of a disease or condition selected from immune deficiency, acquired immune deficiency syndrome (AIDS), myeloperoxidase deficiency, Wiskott-Aldrich syndrome, chronic granulomatous disease, hyper-IgM syndromes, leukocyte adhesion deficiency, Chediak-Higashi syndrome, and severe combined immunodeficiency.

The invention discloses a preparation method of an AIDS (acquired immune deficiency syndrome) virus affinity adsorbent. According to the method, amino acid is utilized to process virus adsorption microspheres connected with ligands, the ligands on the virus adsorption microspheres are combined more firmly, so that the probability and the speed of falling of the AIDS virus affinity adsorbent are reduced, and the safety of the AIDS virus affinity adsorbent during applying is improved.

The invention relates to a phosphonate prodrug of an adenine derivative and medical application of the phosphonate prodrug. Specifically, the invention relates to a compound shown in a general formula (I) or an optical isomer, or a pharmaceutical salt, or a hydrate or a solvate of the compound, and application of the compound or the optical isomer, or the pharmaceutical salt, or the hydrate or the solvate of the compound to preparation of medicines for curing virus infective diseases, especially hepatitis B (HBV) and acquired immune deficiency syndrome (HIV), wherein the definitions of all substituents in the general formula (I) are the same as the definitions in the specification.

This invention relates to a novel polypeptide involving in the modulation of central nervous system function, circulatory function, immune function, gastrointestinal function, metabolic function, reproductive function, etc., it can be used as a drug for treating or preventing a variety of diseases, e.g. HIV infection or AIDS (acquired immune deficiency syndrome) or the like.

The invention discloses a preparation method of intermediate cyclopropyl acetylene of anti-AIDS (acquired immune deficiency syndrome) drug efavirenz. The preparation method comprises the steps of performing a reaction in an organic solvent by taking cyclopropyl methyl ketone as a raw material and phosphorus pentachloride as a chlorinating agent by the action of a catalyst to generate alpha, alpha-dichloroethyl cyclopropane and phosphorus oxychloride, performing decompressed rectification to remove phosphorus oxychloride, removing part of hydrogen chloride from alpha, alpha-dichloroethyl cyclopropane by the action of triethylamine to generate alpha-chlorovinyl cyclopropane, and further removing part of hydrogen chloride by the action of strong base to generate cyclopropyl acetylene. Phosphorus oxychloride is removed by the decompressed rectification; the generation of much phosphorus wastewater due to hydrolysis of phosphorus oxychloride in ice water is avoided; recovered phosphorus oxychloride can be comprehensively utilized by simple rectification; waste gas, wastewater and industrial residue are reduced; the cost is lowered; cyclopropyl acetylene is prepared from alpha-chlorovinyl cyclopropane via a reaction rectification technology; and the method has the advantages of high conversion rate, good selectivity, low energy consumption and the like, and is suitable for industrialproduction.

The invention relates to a triazole ring-containing phenylalanine derivative as well as a preparation method and application thereof. A compound has a structure shown in formula I. The invention alsorelates to a medicine composition containing the compound with the structure shown in the formula I, and also provides application of the compound and the composition containing one or multiple compounds in preparation of medicines for treating and preventing acquired immune deficiency syndrome. (The formula I is shown in the attached figure.).

The present invention relates to novel 3-nitropyridine derivatives, pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the same as active ingredients. Methods of preparing the derivatives and pharmaceutical compositions containing the same are also disclosed. The 3-nitropyridine derivatives of the present invention, due to their inhibitory activity against the proliferation of human immunodeficiency virus (HIV) as well as hepatitis B virus (HBV), can be used as therapeutic agents as well as preventive agents for hepatitis B and acquired immune deficiency syndrome (AIDS).

The present application discloses compounds of formula (I) wherein X is ═O, ═S, ═NH, ═NOH and ═NO-Me; A is —C(═O)—, —S(═O)2—, —C(═S)— and P(═O)(R5)—; B is, —O—, —(CH2)3-6—, and O—(CH2)2-5—; D is, —O—, —CR7R8— and —NR9; m is 0-12, n is 0-12, m+n is 1-20; p is 0-4; R1 is opt.sub. heteroaryl; and pharmaceutically acceptable salts thereof, and prodrugs thereof. The application also discloses the compound for use as a medicament for the treatment of a disease or a condition caused by an elevated level of nicotinamide phosphoribosyltransferase (NAMPRT), e.g. inflammatory and tissue repair disorders; dermatosis; autoimmune diseases, Alzheimers disease, stroke, athersclerosis, restenosis, diabetes, glomerulonephritis, cancer, cachexia, inflammation associated with infection and certain viral infections, including Acquired Immune Deficiency Syndrome (AIDS), adult respiratory distress syndrome, ataxia telengiectasia.

The invention relates to a simple, convenient and high-efficiency synthesis method of 4-chloro-2-trifluoroacetylaniline and analogs thereof. The 4-chloro-2-trifluoroacetylaniline can be used as a key midbody for synthesizing the anti-AIDS (Acquired Immune Deficiency Syndrome) drug efavirenz.

The present invention relates to select peptides of the carboxy terminal and aminoterminal portion of the beta unit of hCG and pharmaceutically acceptable derivatives thereof that can be used for controlling retroviral, e.g., human immunodeficiency virus (BV infections. The invention comprises a method in vitro as well as in vivo for prevention and / or treatment of acquired immune deficiency syndrome (AIDS) at pharmacological doses of beta hCG-derived peptides and pharmaceutically acceptable derivatives thereof which are sufficient to exert an anti-HIV effect for a sufficient period of time.

The invention discloses an AIDS (acquired immune deficiency syndrome) personnel behavior analysis method based on deep learning. The method comprises the following steps: acquiring user behavior data;and based on the user behavior data, analyzing the multi-dimensional space-time information of the user, and constructing a user behavior portrait. Behavior portraying is performed on the AIDS patient based on network, geographic position and social communication behavior analysis, and descriptive label attributes for the user are constructed in multiple dimensions such as network, geographic position and social communication. The label attributes are utilized to describe and outline the real personal characteristics of the AIDS patient in multiple aspects, and are used for describing relatedcharacteristics, behaviors and preferences. Potential social communication rules of AIDS crowds are discovered, high-risk AIDS crowds, potential AIDS propagators and AIDS propagation paths are discovered, and the AIDS intervention link work is assisted to be intervened in advance.

The invention discloses an Aapplication of a benzamide compound in preparation of a medicine for activating latent human immunodeficiency viruses, and an application of a composition of the benzamide compound and one or more anti-human immunodeficiency virus medicines in preparation of a medicine for inhibiting and / or eliminating latent human immunodeficiency viruses. Due to adoption of the medicine, the latent human immunodeficiency viruses can be efficiently and continuously activating latent human immunodeficiency viruses for a long time, and thus acquired immune deficiency syndrome treatment is possible.

The present invention belongs to the field of pharmaceutical industry and relates to dosage forms comprising active pharmaceutical ingredients (API) such as tadalafil, simvastatin, fenofibrate and lovastatin that are practically insoluble in water, adsorbed on a carrier. Furthermore it relates to an adsorbate comprising API being practically insoluble in water and to a process for the preparation of said adsorbate with non-polar solvent (s) such as chlorinated hydrocarbon, diisopropylethes and hexane. Furthermore the invention relates to a process for the preparation of the dosage form, as well as to the use of the adsorbate for the preparation of the dosage form. Moreover it relates to the dosage form for use in the treatment of erectile dysfunction, human immunodeficiency virus (HIV) infections and / or Acquired Immune Deficiency Syndrome (AIDS).

A natural pharmaceutical preparation for treating hypoproteinemia, includes at least one member selected from the group consisting of a drug of increasing human serum albium, a drug of improving and enhance immunity, a drug of treating hepatitis B, a drug of treating Hepatitis C, a drug of treating acquired immune deficiency syndrome (AIDS), a drug of treating Tuberculosis, a drug of treat Fibrosis, a drug of treating hydrothorax, a drug of easing pain, a drug of stopping diarrhea, a drug of arresting coughing, a drug of reducing inflammation, and a drug of increasing urine.

The invention discloses application of parthenolide as a platelet-activating factor (PAF) inhibitor. The parthenolide can be used as a safe PAF antagonist to be applied to treatment, auxiliary treatment and prevention of diseases such as thrombus, atherosclerosis, ischemic cardio-vascular disease, cerebral ischemia, acute pancreatitis, endotoxic shock, asthma, hepatic fibrosis and hepatocirrhosis, injury of nerve, gastrointestinal ulcer and necrosis, psoriasis, systemic lupus erythematosus and acquired immune deficiency syndrome related to platelet-activating factor.

The invention discloses an artemisia scoparia extractive and a production method and applications thereof. The artemisia scoparia extractive contains 25-75 percent of a flavonoid component; the production method of the artemisia scoparia extractive comprises the following steps: 1. crudely extracting the overground part or herba of the artemisia scoparia by water or ethanol; 2. adding anhydrous ethyl alcohol to the extracting solution after filtration and concentration, standing and precipitating, and filtering the sediment to obtain ethanol solution; 3. concentrating the obtained ethanol solution, adjusting the pH value, conducting adsorption on a macroporous resin and / or polyamide resin chromatographic column; 4. conducting gradient elution by 10%-90% ethanol, collecting the ethanol eluent and merging; and 5. concentrating the eluent, recovering the ethanol, and drying under reduced pressure, thus obtaining the required artemisia scoparia extractive. Proved by the experimental study,the artemisia scoparia extractive has remarkable effects on resisting influenza viruses, hepatitis B virus and human immunodeficiency virus, and safe oral drug administration, and can be used for preparing broad-spectrum antiviral drugs for treating influenza, hepatitis B and acquired immune deficiency syndrome.